Single answer
Is argenx SE (ARGX) a buy or sell?
4starter turns market data into one clear verdict you can act on.
Create a free account to save tickers and track your signals.
Log in to turn on watchlist alerts.
Decision snapshot
Everything you need to act fast, in one glance.
What is the conclusion?
Right now our advanced algorithms say:
$1 invested is now $0.99 or -1.22%
(In 16 weeks 2 days 22 hours 30 minutes and 49 seconds .)
Do analysts agree?
We compare consensus targets with today's price.
Consensus target for argenx SE is $1,028.21, which is $211.26 (25.86%) above the current price today's price.
Low target: $858.00 | High target: $1,317.00
Latest analyst updates
Recent rating and price target changes for this stock.
Company snapshot
A quick overview of the business and its public profile.
argenx SE a biotechnology company engages in the developing of various therapies for the treatment of autoimmune diseases in the United States Japan Europe Middle East Africa and China Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis immune thrombocytopenia pemphigus vulgaris generalized myasthenia gravis chronic inflammatory demyelinating polyneuropathy thyroid eye disease bullous pemphigoid myositis primary sjogrens syndrome postcovid postural orthostatic tachycardia syndrome membranous nephropathy lupus nephropathy ancaassociated vasculitis and antibody mediated rejection ENHANZE SC Empasiprubart for multifocal motor neuropath delayed graft function and dermatomyositis and ARGX119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis The company is developing ARGX213 targets FcRn ARGX121 and ARGX220 targets immune system ARGX109 targets IL6 ARGX118 for inflammation and ARGX109 as well as cusatuzumab ARGX112 ARGX114 and ARGX115 It owns VYVGART VYVGART HYTRULO VYVDURA ARGENX ABDEG NHANCE SIMPLE ANTIBODY and ARGENXMEDHUB The company has strategic partnership with AbbVie SARL Zai Lab Limited and LEO Pharma AS and collaboration and license agreement with Genor Biopharma Co Ltd Universite Catholique de Louvain Sopartec SA NYU Langone Health Leiden University Medical Center AgomAb Therapeutics NV Broteio Pharma BV VIB vzw University of Texas BioWa Inc and Shire International GmbH It has collaboration agreement with Genmab AS to discover develop and commercialize novel therapeutic antibodies with applications in immunology and oncology as well as a strategic collaboration with IQVIA Holdings Inc to provide safety systems and services argenx SE was incorporated in 2008 and is based in Amsterdam the Netherlands
Website: https://www.argenx.com
Rates and inflation backdrop
US inflation for January 2026 was 0.17%. Over the last 12 months, inflation is 2.83%. The 10-year yield is 4.04 and is down -0.110 over the last 30 days.
Inflation sensitivity
Debt ratio: 0.01. Cash flow to debt ratio: 11.12. Net profit margin: 37.50%. Inflation risk score: low (0.00/1).
Dividend history check
We cannot find any recorded dividends paid in our systems.
Trading liquidity
Yes, the average daily trading liquidity for argenx SE is $296.2M. You should therefore be able to get in and out of your positions relatively fast.
10-year return check
We cannot find data for argenx SE 10 years ago, but if you had invested on 2017-05-18 when the price was $23.00, you would have made a profit of $793.95 per share or 3,451.96%.
Why this answer
We combine price momentum, volatility, and trend signals to simplify the decision to one word.
Signal engine scans price, trend, and momentum indicators.
Targets and sentiment are checked against the live quote.
We keep the output simple: buy, sell, or hold.
Analyst consensus
How Wall Street targets compare to today's price.